BOOP as a rare complication of gemcitabine therapy

Gemcitabine is commonly used in combination with carboplatin in patients with advanced non-small-cell lung cancer (NSCLC). Gemcitabine has good clinical activity against NSCLC and is well tolerated by the patients. Myelosuppression is its dose-limiting toxicity. A potential side effect of gemcitabin...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kawsar, Hameem I, Spiro, Timothy P, Cocco, Amy, Daw, Hamed A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2011
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3143343/
https://ncbi.nlm.nih.gov/pubmed/22689600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr.04.2011.4055
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg